# Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis

> **NCT04049448** · PHASE2 · COMPLETED · sponsor: **Abivax S.A.** · enrollment: 40 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** ABX464

## Key facts

- **NCT ID:** NCT04049448
- **Lead sponsor:** Abivax S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-25
- **Primary completion:** 2023-01-23
- **Final completion:** 2023-01-23
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-11-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04049448

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04049448, "Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT04049448. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*